Oppenheimer analyst Justin Kim downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Perform.
Piper Sandler Maintains Overweight on Devon Energy, Lowers Price Target to $89
Piper Sandler analyst Mark Lear maintains Devon Energy (NYSE:DVN) with a Overweight and lowers the price target from $96 to $89.